Background: Impact of N-acetylation phenotype on the process of restenosis.
Purpose: the evaluation of prognostic value of N-acetylation phenotype for the determination of BMS condition after coronary stenting.
Material and methods: retrospective study included 100 male patients who received 116 coronary BMS for chronic CHD. The patients have been selected for the study after control coronary angiography performed in 7,2±2,2 months after PCI. The patients were divided into two groups: with in-stent stenosis (Group 1, n=50) and with good mid-term results (Group 2, control, n=50). Baseline angiographic data of patients and immediate results of PCI were evaluated by two independent experts. The standard Sulphadimine was used as the test-agent for N-acetylation phenotype determination. After single peroral intake of 500 mg of Sulphadimine, the urine has been collected for 6 hours, and than the ratio of pro-metabolized (N-acetyl-sulphadimine) and non-metabolized sulphadimine in urine was determined with the help of high-effective liquid chromatography.
Results: among the studied patients, there were 38% of slow acetylators and 62% of fast acetylators.
The analysis of the distribution of acetylation phenotype on groups 1 and 2 revealed high statistically significant prevalence of fast acetylators among patients with in-stent stenosis in the mid-term after PCI, Р=0,0006.
Conclusions: we revealed reliable direct correlation between the velocity of acetylation processes and the degree of in-stent stenosis after coronary stenting with BMS in patients with chronic coronary heart disease.
